References
- Venkatesan P, Rao MN. Structure-activity relationships for the inhibition of lipid peroxidation and the scavenging of free radicals by synthetic symmetrical curcumin analogues. J Pharm Pharmacol. 2000;52(9):1123–1128.
- Srimal RC, Dhawan BN. Pharmacology of diferuloyl methane (curcumin), a non-steroidal anti-inflammatory agent. J Pharm Pharmacol. 1973;25(6):447–452.
- Huang MT, Lou YR, Ma W, Newmark HL, Reuhl KR, Conney AH. Inhibitory effects of dietary curcumin on forestomach, duodenal, and colon carcinogenesis in mice. Cancer Res. 1994;54(22):5841–5847.
- Arun N, Nalini N. Efficacy of turmeric on blood sugar and polyol pathway in diabetic albino rats. Plant Foods Hum Nutr. 2002;57(1):41–52.
- Sui Z, Salto R, Li J, Craik C, Ortiz de Montellano PR. Inhibition of the HIV-1 and HIV-2 proteases by curcumin and curcumin boron complexes. Bioorg Med Chem. 1993;1(6):415–422.
- Quiles JL, Mesa MD, Ramírez-Tortosa CL, et al. Curcuma longa extract supplementation reduces oxidative stress and attenuates aortic fatty streak development in rabbits. Arterioscler Thromb Vasc Biol. 2002;22(7):1225–1231.
- Morimoto T, Sunagawa Y, Kawamura T, et al. The dietary compound curcumin inhibits p300 histone acetyltransferase activity and prevents heart failure in rats. J Clin Invest. 2008;118(3):868–878.
- Wongcharoen W, Phrommintikul A. The protective role of curcumin in cardiovascular diseases. Int J Cardiol. 2009;133(2):145–151.
- Mishra S, Palanivelu K. The effect of curcumin (turmeric) on Alzheimer’s disease: An overview. Ann Indian Acad Neurol. 2008;11(1):13–19.
- Dhillon N, Aggarwal BB, Newman RA, et al. Phase II trial of curcumin in patients with advanced pancreatic cancer. Clin Cancer Res. 2008;14(14):4491–4499.
- Obata K, Kojima T, Masaki T, et al. Curcumin prevents replication of respiratory syncytial virus and the epithelial responses to it in human nasal epithelial cells. PLoS One. 2013;8(9):e70225.
- Cheng AL, Hsu CH, Lin JK, et al. Phase I clinical trial of curcumin, a chemopreventive agent, in patients with high-risk or pre-malignant lesions. Anticancer Res. 2001;21(4B):2895–2900.
- Heger M, van Golen RF, Broekgaarden M, Michel MC. The molecular basis for the pharmacokinetics and pharmacodynamics of curcumin and its metabolites in relation to cancer. Pharmacol Rev. 2014;66(1):222–307.
- Anand P, Kunnumakkara AB, Newman RA, Aggarwal BB. Bioavailability of curcumin: problems and promises. Mol Pharm. 2007;4(6):807–818.
- Mishra S, Kapoor N, Mubarak Ali A, et al. Differential apoptotic and redox regulatory activities of curcumin and its derivatives. Free Radic Biol Med. 2005;38(10):1353–1360.
- Costi R, Di Santo R, Artico M, et al. Cinnamoyl compounds as simple molecules that inhibit p300 histone acetyltransferase. J Med Chem. 2007;50(8):1973–1977.
- Zhang Q, Fu Y, Wang HW, Gong T, Qin Y, Zhang ZR. Synthesis and cytotoxic activity of novel curcumin analogues. Chin Chem Lett. 2008;19(3):281–285.
- Qiu X, Du Y, Lou B, et al. Synthesis and identification of new 4-arylidene curcumin analogues as potential anticancer agents targeting nuclear factor-κB signaling pathway. J Med Chem. 2010;53(23):8260–8273.
- Huo YP, Shao WY, An LK, Bu XZ, Gu LQ. Synthesis of new 2-aryl-6- styryl-2, 3-dihydropyridin-4(1H)-one derivatives from curcuminoids. Chin Chem Lett. 2009;20(11):1291–1295.
- Sahu PK, Sahu PK, Gupta SK, Thavaselvam D, Agarwal DD. Synthesis and evaluation of antimicrobial activity of 4H-pyrimido[2,1-b]benzothiazole, pyrazole and benzylidene derivatives of curcumin. Eur J Med Chem. 2012;54:366–378.
- Labbozzetta M, Baruchello R, Marchetti P, et al. Lack of nucleophilic addition in the isoxazole and pyrazole diketone modified analogs of curcumin; implications for their antitumor and chemosensitizing activities. Chem Biol Interact. 2009;181(1):29–36.
- Fuchs JR, Pandit B, Bhasin D, et al. Structure-activity relationship studies of curcumin analogues. Bioorg Med Chem Lett. 2009;19(7):2065–2069.
- Jayaraj RL, Tamilselvam K, Manivasagam T, Elangovan N. Neuroprotective effect of CNB-001, a novel pyrazole derivative of curcumin on biochemical and apoptotic markers against rotenone-induced SK-N-SH cellular model of Parkinson’s disease. J Mol Neurosci. 2013;51(3):863–870.
- Mayadevi M, Sherin DR, Keerthi VS, Rajasekharan KN, Omkumar RV. Curcumin is an inhibitor of calcium/calmodulin dependent protein kinase II. Bioorg Med Chem. 2012;20(20):6040–6047.
- Lapchak PA, Schubert DR, Maher PA. Delayed treatment with a novel neurotrophic compound reduces behavioral deficits in rabbit ischemic stroke. J Neurochem. 2011;116(1):122–131.
- López SN, Ramallo IA, Sierra MG, Zacchino SA, Furlan RL. Chemically engineered extracts as an alternative source of bioactive natural product-like compounds. Proc Natl Acad Sci U S A. 2007;104(2):441–444.
- Méndez L, Salazar MO, Ramallo IA, Furlan RL. Brominated extracts as source of bioactive compounds. ACS Comb Sci. 2011;13(2):200–204.
- Wang SY, Kuo YH, Chang HN, et al. Profiling and characterization antioxidant activities in Anoectochilus formosanus hayata. J Agric Food Chem. 2002;50(7):1859–1865.
- Kikuchi H, Sakurai K, Oshima Y. Development of diversity-enhanced extracts of Curcuma zedoaria and their new sesquiterpene-like compounds. Org Lett. 2014;16(7):1916–1919.
- Li Y, Ooi LS, Wang H, But PP, Ooi VE. Antiviral activities of medicinal herbs traditionally used in southern mainland China. Phytother Res. 2004;18(9):718–722.
- Wu J. Studies on Natural Curcuminoids and their Combinatorial Modification [doctoral thesis]. Guangzhou: Jinan University; 2012.